46
MEDYA
TR
EN
Home
Genel
News Detail
Morning Star
May 30, 2026
|
22:00
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
...
Full Story at Source
Related News
As Big Tech's power demand surges, data -2
As Big Tech's power demand surges, data centers bring utilities a huge new profit center
Arne Slot sacked: Why did Liverpool called time on head coach?
China's next export shock walks on two legs - and costs less than a used car
